Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dinmet-XL is a fixed-dose combination pharmaceutical product containing **cilnidipine**, a dual L/N-type calcium channel blocker, and **metoprolol succinate**, a cardioselective beta-1 adrenergic antagonist. The "XL" designation indicates an extended-release formulation, typically applied to the metoprolol component to provide sustained blood pressure control over 24 hours. Cilnidipine acts by inhibiting L-type calcium channels in vascular smooth muscle to induce vasodilation and N-type calcium channels in sympathetic nerve terminals to suppress norepinephrine release, thereby reducing reflex tachycardia. Metoprolol succinate reduces cardiac output and heart rate by selectively blocking beta-1 receptors in the heart. This combination is primarily indicated for the management of hypertension, particularly in patients where monotherapy is insufficient or where the dual mechanism of sympathetic suppression and vasodilation is clinically preferred.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cilnidipine + metoprolol succinate.